Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Key claim: This phase 1/2 trial investigates whether tasquinimod alone or combined with ruxolitinib can control primary myelofibrosis, post-PV MF, or post-ET MF.
Abstract
To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.
Why this matters
Tasquinimod brings a mechanistically novel S100A9/HDAC4 inhibitor into MF, targeting myeloid-derived suppressor cell biology and epigenetic regulation rather than JAK signaling directly. By enrolling primary, post-PV, and post-ET MF together, the trial reinforces the convergent fibrotic-phase biology shared across these MPN subtypes while preserving the option to detect subtype-specific response differences. It expands the growing portfolio of ruxolitinib-combination strategies probing whether non-JAK pathways can deepen responses in MF.